WASHINGTON, Aug. 21 -- National Institutes of Health has issued a notice called: Government Owned Invention Available for License: Matched Patient-Derived 3D Isocitrate Dehydrogenase (IDH)-Mutant Glioma Cell Lines for Modeling Malignant Transformation.
The notice was published in the Federal Register on Aug. 21 by Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute.
Summary: The National Cancer Institute (NCI) seeks licensees for matched patient-derived 3D Isocitrate Dehydrogenase (IDH)-mutant glioma cell lines, 403L and 403H, generated from the same patient before and after malignant transformation from WHO grade 2 to WHO grade 4 disease. This research material provides an opportunity to study ...